Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results
Date:2/24/2011

building our European organization, increased marketing expenses, legal costs and compensation expense partly offset by decreased medical education expenses.

Our income tax expense was $75.3 million and $41.0 million for the year ended December 31, 2010 and 2009, respectively.  The effective tax rate in 2010 was 37.5 percent compared to 137.0 percent in 2009.  The effective tax rate in 2010 exceeded the federal statutory tax rate due to state income taxes and certain share-based compensation that is not tax deductible.  The effective tax rate in 2009 exceeded the statutory tax rate because of a goodwill impairment charge which was not deductible for tax purposes and state income taxes, partially offset by an orphan drug credit.

Working Capital HighlightsAt December 31, 2010, our working capital was $561.0 million compared to $406.4 million at the end of 2009 as we generated $193.5 million in cash flow from operations during 2010.

Looking ahead in 2011ViroPharma is reiterating its guidance for the year 2011 as a convenience to investors.  The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties.  For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2011, ViroPharma expects the following:

  • Net Cinryze sales are expected to be $235 to $260 million.

  • Research and development (R&D) and selling, general and administrative (SG&A) expenses are expected to be $170 to $190 million.  

  • Conference Call and WebcastViroPharma is hosting a live teleconference and webcast with senior management to discuss the financial announcement, guidance, and other business results on February 24, 2011 at 9:00 a.m. Eastern. To participate in the conference ca
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. ViroPharma to Present at Three September Healthcare Conferences
    2. ViroPharma to Present at Three October Healthcare Conferences
    3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
    4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
    5. ViroPharma to Present at Three November Healthcare Conferences
    6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
    7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
    8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
    9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
    10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
    11. ViroPharma to Present at Two June Healthcare Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... Station, Texas (PRWEB) September 18, 2014 ... System Chancellor John Sharp, Texas A&M Health Science ... the U.S. Department of Health and Human Services ... today dedicated a national pandemic influenza vaccine manufacturing ... serve as an anchor for the Texas A&M ...
    (Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global and Chinese Stem Cell Industry Report, 2014-2017" ... are undifferentiated biological cells that can differentiate into specialized ... stem cells. Stem cell therapy can be applied to ... system disease), nervous system diseases, damage or lesion of ...
    (Date:9/18/2014)... 2014 Research and Markets has ... Industry Report 2014" report to their offering. ... is a professional and in-depth study on the current ... The report provides a basic overview of the industry ... human albumin market analysis is provided for the international ...
    (Date:9/18/2014)... Leatherwood Plastics has selected Vycom’s Flametec ... competitive in the semiconductor, clean room and medical ... product quality and productivity, according to Dwight Leatherwood, ... 1980 in Lewisville, TX, Leatherwood Plastics ... the business. Much of Leatherwood’s equipment building relies ...
    Breaking Biology Technology:Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2
    ... pirfenidone role in treatment of patients with IPF -- Ground-breaking ... Strong data from 14-day triple combination study of ITMN-191 in ... (Nasdaq: ITMN ) today announced results from operations ... InterMune reported a net loss for the first quarter ...
    ... ERES ), a leading provider of centralized ECG, ... device, and related industries, announced today results for the first ... refer to changes from the same period a year ago.Highlights ... , Quarterly ...
    ... 30 Resonant Medical, an innovator in 3D ... appointment of Stephen Whisenhunt to the position of ... will lead the Company,s growing global sales team ... than 18 years of radiation oncology industry experience ...
    Cached Biology Technology:InterMune Reports First Quarter 2009 Financial Results and Business Highlights 2InterMune Reports First Quarter 2009 Financial Results and Business Highlights 3InterMune Reports First Quarter 2009 Financial Results and Business Highlights 4InterMune Reports First Quarter 2009 Financial Results and Business Highlights 5InterMune Reports First Quarter 2009 Financial Results and Business Highlights 6InterMune Reports First Quarter 2009 Financial Results and Business Highlights 7InterMune Reports First Quarter 2009 Financial Results and Business Highlights 8InterMune Reports First Quarter 2009 Financial Results and Business Highlights 9InterMune Reports First Quarter 2009 Financial Results and Business Highlights 10InterMune Reports First Quarter 2009 Financial Results and Business Highlights 11InterMune Reports First Quarter 2009 Financial Results and Business Highlights 12InterMune Reports First Quarter 2009 Financial Results and Business Highlights 13ERT Reports First Quarter 2009 Results 2ERT Reports First Quarter 2009 Results 3ERT Reports First Quarter 2009 Results 4ERT Reports First Quarter 2009 Results 5ERT Reports First Quarter 2009 Results 6ERT Reports First Quarter 2009 Results 7ERT Reports First Quarter 2009 Results 8ERT Reports First Quarter 2009 Results 9Resonant Medical Expands Sales Organization with Appointment of Vice President of Global Sales and Marketing 2
    (Date:9/19/2014)... a species which over thousands of years has adapted to ... substance that makes the cold dangerous for you. , This ... , and the cold provoking substance, called nonylphenol, comes from ... is suspected of being a endocrine disruptor, but when entering ... worm,s ability to protect the cells in its body from ...
    (Date:9/19/2014)... legume plants regulate their symbiotic relationship with soil ... through the plant structure from leaves into the ... in the roots. This collaborative study was conducted ... Biology, the Graduate University for Advanced Studies (SOKENDAI), ... in Japan. , Legumes, an important plant ...
    (Date:9/18/2014)... Bulletin study uses tree rings to document arroyo ... in northern New Mexico, USA. By determining burial dates ... were able to precisely date arroyo sedimentary beds 30 ... with aerial imagery, LiDAR, longitudinal profiles, and repeat surveys ... are deep, oversized channels that have vertical or steeply ...
    Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3For legume plants, a new route from shoot to root 2Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
    ... and Duke University have developed nanoscale "patches" that can ... more responsive to signals that control cell activity. The ... engineering research. The research takes advantage of the ... via physical contact. Specifically, when targeted receptors on the ...
    ... mainland - are taking the lead in making plans to ... Diana Reckien, of Columbia University in the US, in a ... analysed the relevant strategic policies and planning documents of 200 ... in every three European cities has no plans on the ...
    ... "smart": too elementary to be able to reproduce by themselves, ... of their own DNA so that it is transcribed by ... inject their own genetic material into the cells they infect. ... (the International School for Advanced Studies in Trieste), has studied ...
    Cached Biology News:Researchers use nanoscale 'patches' to sensitize targeted cell receptors 2The reality behind Europe's response to climate change 2Tidy knots are faster 2
    Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
    B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
    Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
    ...
    Biology Products: